Cargando…

Machine learning methods for accurately predicting survival and guiding treatment in stage I and II hepatocellular carcinoma

Accurately predicting survival in patients with early hepatocellular carcinoma (HCC) is essential for making informed decisions about treatment and prognosis. Herein, we have developed a machine learning (ML) model that can predict patient survival and guide treatment decisions. We obtained patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xianguo, Bao, Haijun, Shi, Yongping, Zhu, Wenzhong, Peng, Zuojie, Yan, Lizhao, Chen, Jinhuang, Shu, Xiaogang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10637529/
https://www.ncbi.nlm.nih.gov/pubmed/37960763
http://dx.doi.org/10.1097/MD.0000000000035892
_version_ 1785146517381709824
author Li, Xianguo
Bao, Haijun
Shi, Yongping
Zhu, Wenzhong
Peng, Zuojie
Yan, Lizhao
Chen, Jinhuang
Shu, Xiaogang
author_facet Li, Xianguo
Bao, Haijun
Shi, Yongping
Zhu, Wenzhong
Peng, Zuojie
Yan, Lizhao
Chen, Jinhuang
Shu, Xiaogang
author_sort Li, Xianguo
collection PubMed
description Accurately predicting survival in patients with early hepatocellular carcinoma (HCC) is essential for making informed decisions about treatment and prognosis. Herein, we have developed a machine learning (ML) model that can predict patient survival and guide treatment decisions. We obtained patient demographic information, tumor characteristics, and treatment details from the SEER database. To analyze the data, we employed a Cox proportional hazards (CoxPH) model as well as 3 ML algorithms: neural network multitask logistic regression (N-MLTR), DeepSurv, and random survival forest (RSF). Our evaluation relied on the concordance index (C-index) and Integrated Brier Score (IBS). Additionally, we provided personalized treatment recommendations regarding surgery and chemotherapy choices and validated models’ efficacy. A total of 1136 patients with early-stage (I, II) hepatocellular carcinoma (HCC) who underwent liver resection or transplantation were randomly divided into training and validation cohorts at a ratio of 3:7. Feature selection was conducted using Cox regression analyses. The ML models (NMLTR: C-index = 0.6793; DeepSurv: C-index = 0.7028; RSF: C-index = 0.6890) showed better discrimination in predicting survival than the standard CoxPH model (C-index = 0.6696). Patients who received recommended treatments had higher survival rates than those who received unrecommended treatments. ML-based surgery treatment recommendations yielded higher hazard ratios (HRs): NMTLR HR = 0.36 (95% CI: 0.25–0.51, P < .001), DeepSurv HR = 0.34 (95% CI: 0.24–0.49, P < .001), and RSF HR = 0.37 (95% CI: 0.26–0.52, P = <.001). Chemotherapy treatment recommendations were associated with significantly improved survival for DeepSurv (HR: 0.57; 95% CI: 0.4–0.82, P = .002) and RSF (HR: 0.66; 95% CI: 0.46–0.94, P = .020). The ML survival model has the potential to benefit prognostic evaluation and treatment of HCC. This novel analytical approach could provide reliable information on individual survival and treatment recommendations.
format Online
Article
Text
id pubmed-10637529
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-106375292023-11-15 Machine learning methods for accurately predicting survival and guiding treatment in stage I and II hepatocellular carcinoma Li, Xianguo Bao, Haijun Shi, Yongping Zhu, Wenzhong Peng, Zuojie Yan, Lizhao Chen, Jinhuang Shu, Xiaogang Medicine (Baltimore) 4500 Accurately predicting survival in patients with early hepatocellular carcinoma (HCC) is essential for making informed decisions about treatment and prognosis. Herein, we have developed a machine learning (ML) model that can predict patient survival and guide treatment decisions. We obtained patient demographic information, tumor characteristics, and treatment details from the SEER database. To analyze the data, we employed a Cox proportional hazards (CoxPH) model as well as 3 ML algorithms: neural network multitask logistic regression (N-MLTR), DeepSurv, and random survival forest (RSF). Our evaluation relied on the concordance index (C-index) and Integrated Brier Score (IBS). Additionally, we provided personalized treatment recommendations regarding surgery and chemotherapy choices and validated models’ efficacy. A total of 1136 patients with early-stage (I, II) hepatocellular carcinoma (HCC) who underwent liver resection or transplantation were randomly divided into training and validation cohorts at a ratio of 3:7. Feature selection was conducted using Cox regression analyses. The ML models (NMLTR: C-index = 0.6793; DeepSurv: C-index = 0.7028; RSF: C-index = 0.6890) showed better discrimination in predicting survival than the standard CoxPH model (C-index = 0.6696). Patients who received recommended treatments had higher survival rates than those who received unrecommended treatments. ML-based surgery treatment recommendations yielded higher hazard ratios (HRs): NMTLR HR = 0.36 (95% CI: 0.25–0.51, P < .001), DeepSurv HR = 0.34 (95% CI: 0.24–0.49, P < .001), and RSF HR = 0.37 (95% CI: 0.26–0.52, P = <.001). Chemotherapy treatment recommendations were associated with significantly improved survival for DeepSurv (HR: 0.57; 95% CI: 0.4–0.82, P = .002) and RSF (HR: 0.66; 95% CI: 0.46–0.94, P = .020). The ML survival model has the potential to benefit prognostic evaluation and treatment of HCC. This novel analytical approach could provide reliable information on individual survival and treatment recommendations. Lippincott Williams & Wilkins 2023-11-10 /pmc/articles/PMC10637529/ /pubmed/37960763 http://dx.doi.org/10.1097/MD.0000000000035892 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC) (https://creativecommons.org/licenses/by-nc/4.0/) , where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.
spellingShingle 4500
Li, Xianguo
Bao, Haijun
Shi, Yongping
Zhu, Wenzhong
Peng, Zuojie
Yan, Lizhao
Chen, Jinhuang
Shu, Xiaogang
Machine learning methods for accurately predicting survival and guiding treatment in stage I and II hepatocellular carcinoma
title Machine learning methods for accurately predicting survival and guiding treatment in stage I and II hepatocellular carcinoma
title_full Machine learning methods for accurately predicting survival and guiding treatment in stage I and II hepatocellular carcinoma
title_fullStr Machine learning methods for accurately predicting survival and guiding treatment in stage I and II hepatocellular carcinoma
title_full_unstemmed Machine learning methods for accurately predicting survival and guiding treatment in stage I and II hepatocellular carcinoma
title_short Machine learning methods for accurately predicting survival and guiding treatment in stage I and II hepatocellular carcinoma
title_sort machine learning methods for accurately predicting survival and guiding treatment in stage i and ii hepatocellular carcinoma
topic 4500
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10637529/
https://www.ncbi.nlm.nih.gov/pubmed/37960763
http://dx.doi.org/10.1097/MD.0000000000035892
work_keys_str_mv AT lixianguo machinelearningmethodsforaccuratelypredictingsurvivalandguidingtreatmentinstageiandiihepatocellularcarcinoma
AT baohaijun machinelearningmethodsforaccuratelypredictingsurvivalandguidingtreatmentinstageiandiihepatocellularcarcinoma
AT shiyongping machinelearningmethodsforaccuratelypredictingsurvivalandguidingtreatmentinstageiandiihepatocellularcarcinoma
AT zhuwenzhong machinelearningmethodsforaccuratelypredictingsurvivalandguidingtreatmentinstageiandiihepatocellularcarcinoma
AT pengzuojie machinelearningmethodsforaccuratelypredictingsurvivalandguidingtreatmentinstageiandiihepatocellularcarcinoma
AT yanlizhao machinelearningmethodsforaccuratelypredictingsurvivalandguidingtreatmentinstageiandiihepatocellularcarcinoma
AT chenjinhuang machinelearningmethodsforaccuratelypredictingsurvivalandguidingtreatmentinstageiandiihepatocellularcarcinoma
AT shuxiaogang machinelearningmethodsforaccuratelypredictingsurvivalandguidingtreatmentinstageiandiihepatocellularcarcinoma